AtaiBeckley Inc. 4

Director Sabrina Martucci Johnson had all outstanding AtaiBeckley Inc. stock options cancelled and cashed out (with CVRs) at the $6.75-per-share merger price in connection with Eli Lilly’s acquisition.

On September 11, 2026, in connection with the closing of the Eli Lilly & Co. acquisition of AtaiBeckley Inc., all of Sabrina Martucci Johnson’s outstanding AtaiBeckley stock options were automatically cancelled and converted into the right to receive cash and contingent value rights (CVRs) based on the $6.75 per share merger consideration. Specifically, five tranches of options with exercise prices of $3.84, $1.88, $1.34, $2.25, and $4.50 per share and covering 64,000, 64,000, 103,000, 103,000, and 121,968 shares, respectively, were cancelled at the effective time of the merger and exchanged for a cash payment equal to the spread between $6.75 and the relevant strike price multiplied by the number of underlying shares, plus one CVR per share with potential additional cash of up to $2.50 per CVR upon achievement of specified milestones. These transactions reflect a change-in-control treatment of equity awards rather than discretionary insider trading, and after cancellation Ms. Johnson no longer held these options, with resulting common stock positions reported as zero for each related line item.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036378

Alert Tier

6